201 related articles for article (PubMed ID: 22480280)
1. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
2. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Wencker M; Fuhrmann B; Banik N; Konietzko N;
Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951
[TBL] [Abstract][Full Text] [Related]
4. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.
Tonelli AR; Rouhani F; Li N; Schreck P; Brantly ML
Int J Chron Obstruct Pulmon Dis; 2009; 4():443-52. PubMed ID: 20054436
[TBL] [Abstract][Full Text] [Related]
5. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
6. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
8. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
10. The direct medical costs of alpha(1)-antitrypsin deficiency.
Mullins CD; Huang X; Merchant S; Stoller JK;
Chest; 2001 Mar; 119(3):745-52. PubMed ID: 11243952
[TBL] [Abstract][Full Text] [Related]
11. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1-antitrypsin and other proteinase inhibitors.
Miravitlles M
Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
[TBL] [Abstract][Full Text] [Related]
13. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
15. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population.
Silva GE; Sherrill DL; Guerra S; Barbee RA
Chest; 2003 May; 123(5):1435-40. PubMed ID: 12740258
[TBL] [Abstract][Full Text] [Related]
17. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
18. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
20. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]